Daniela Cihakova, Rajni B. Sharma, DeLisa Fairweather, Marina Afanasyeva, and Noel R. Rose
This chapter describes four murine models of autoimmune diseases: two related to autoimmune myocarditis and two related to autoimmune thyroiditis. The first model, Coxsackie virus B3 (CB3)-induced myocarditis, results in the development of acute myocarditis in susceptible as well as resistant mouse strains, whereas chronic myocarditis develops only in genetically susceptible mice. CB3-induced myocarditis closely resembles the course of human myocarditis, which is believed to be initiated by viral infection. Mouse cardiac myosin heavy chain has been identified as the major antigen associated with the late chronic phase of viral myocarditis. The second model is cardiac myosin-induced experimental autoimmune myocarditis (EAM) and, in a modification, cardiac a-myosin heavy chain peptide-induced myocarditis. In the EAM model, cardiac myosin or the relevant peptide in Freund's complete adjuvant (FCA)is injected subcutaneously into mice. The immune response, the histological changes, and the genetic susceptibility seen in EAM are similar to those of CB3-induced myocarditis. The third model is experimental autoimmune thyroiditis (EAT). EAT can be induced in genetically susceptible strains of mice by immunization with mouse thyroglobulin in FCA or lipopolysaccharide. Mice susceptible to EAT have the H-2Ak, H-2As, or H-2Aq alleles. We describe here a standard technique for the induction of EAT; it was developed in our laboratory and is widely used as a model for studying Hashimoto's thyroiditis. The fourth model presented in this chapter is that of spontaneous autoimmune thyroiditis in NOD.H2M mice. These mice express the H-2A* allele on an NOD genetic background and develop spontaneous thyroiditis, which is exacerbated with dietary iodine.
Key Words: Autoimmunity; Coxsackie virus B3 (CB3); Freund's complete adjuvant (FCA); myocarditis; myosin; thyroiditis; NOD.H2M.
From: Methods in Molecular Medicine, Vol. 102: Autoimmunity: Methods and Protocols Edited by: A. Perl © Humana Press Inc., Totowa, NJ
Was this article helpful?